Printer Friendly

UCSF PATENT ALLOWED FOR TRANSDERMAL DIAGNOSTICS FOR GLUCOSE MONITORING

 REDWOOD CITY, Calif., June 18 /PRNewswire/ -- Cygnus Therapeutic Systems (NASDAQ: CYGN), a drug delivery company, announced today that a collaborative research program with the University of California, San Francisco (UCSF) on noninvasive glucose (blood sugar) monitoring technology has resulted in a patent which was recently allowed by the United States Patent and Trademark Office. The technique uses iontophoresis, an established electrically-assisted transport technology, to extract glucose through the intact skin. Richard H. Guy, Ph.D., Professor of Pharmacy and Pharmaceutical Chemistry at UCSF, was studying iontophoresis for drug delivery through the skin when he realized that chemicals were also being extracted from the body through the skin. This insight led him to investigate the potential of iontophoresis in reverse as a diagnostic method. Cygnus has an option to acquire an exclusive license to the resulting patent.
 "We have now tested the feasibility of the approach in humans, and we know we can extract glucose in measurable quantities through intact skin," declared Dr. Guy. "We have preliminary results that show that the extraction can be performed reproducibly in 10 minutes, and that, at least for longer periods of extraction, there is a correlation between the extracted amounts and blood levels. Our next step is to extend these results to diabetic patients."
 Cygnus is conducting research and development on a non-invasive glucose monitoring device incorporating this technology for use by diabetics to more frequently monitor blood glucose levels. Recent results of a research project, the Diabetes Control and Complications Trial, financed by the National Institute of Diabetes and Digestive and Kidney Diseases, has shown that more frequent monitoring enables the diabetic to better control blood sugar levels, significantly reducing the serious complications of diabetes, such as blindness, kidney disease and nerve damage.
 Cygnus, located in Redwood City, Calif., is an innovative developer of advanced transdermal drug delivery systems. Cygnus developed and manufactures Nicotrol(R), the "waking hours nicotine patch," sold in the U.S. and Canada by Warner-Lambert/Parke-Davis, and in Europe (as Nicorette(R)) by Kabi Pharmacia AB. Cygnus has two products for Phase III clinical trials; an estradiol patch to treat menopausal symptoms, and a fentanyl patch for post-operative pain management.
 The company has a development portfolio of more than 14 products. These include eight female hormone replacement therapy patches and transdermal systems for smoking cessation, sedation, analgesia, and treatment of angina, anxiety and hypertension. Two consumer products for oral hygiene and cough suppression are in consumer evaluation.
 In addition to iontophoresis, Cygnus is developing a second generation electrically-assisted transdermal drug delivery technology. Electroporation uses pulsed electrical currents to create temporary reversible pathways through cells and tissues. This proprietary technology is particularly promising for delivery of large proteins and peptides, such as insulin.
 -0- 6/18/93
 /CONTACT: Venus Borden of Cygnus, 415-369-4300/
 (CYGN)


CO: Cygnus Therapeutic Systems ST: California IN: HEA SU:

LD-TM -- NY002 -- 3415 06/18/93 08:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 18, 1993
Words:482
Previous Article:SUMMIT TECHNOLOGY, INC. AGREES TO PURCHASE PATENTS
Next Article:GPS TECHNOLOGIES, INC. ANNOUNCES THE AWARD OF A $59,000,000 CONTRACT WITH THE U.S. NAVY
Topics:


Related Articles
TECHNICAL CHEMICALS AND PRODUCTS, INC. ANNOUNCES CLOSING OF TRANSACTION TO ACQUIRE ASSETS OF PHARMA PATCH, PLC
TECHNICAL CHEMICALS AND PRODUCTS, INC. REPORTS 1ST QUARTER RESULTS
SpectRx, Inc. Expects Rapid Growth -- Building on 1996 Agreements with Abbott Laboratories and Other Strategic Partners
Technical Chemicals & Products Signs Agreement With Taiho Pharmaceutical Co. To Develop Diagnostic Test To Monitor Effectiveness Of A New Drug Product
Technical Chemicals & Products Receives First Order of HealthCheck Products From Eckerd Corp.
Technical Chemicals & Products Receives First Order of HealthCheck Products From Eckerd Corp.
Sontra Medical Granted U.S. Patent for Non-Invasive Body Fluid Sampling and Analysis.
Non-Invasive Glucose Monitoring - Solianis Monitoring AG.
Materials for fabricating biosensors for transdermal glucose monitoring.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters